Off-label use (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Off-label use" in English language version.

refsWebsite

Global rank English rank

14nih.gov

4^th place

10doi.org

2^nd place

4web.archive.org

1^st place

3nytimes.com

7^th place

2fda.gov

447^th place

338^th place

1npr.org

92^nd place

72^nd place

1cancer.gov

1,684^th place

1,350^th place

1medscape.com

719^th place

636^th place

1webmd.com

1,169^th place

1,075^th place

1medicinenet.com

3,840^th place

3,358^th place

1consumerreports.org

4,720^th place

2,843^rd place

1axios.com

1,716^th place

973^rd place

1washingtonpost.com

34^th place

27^th place

1cornell.edu

332^nd place

246^th place

1druganddevicelawblog.com

low place

1usdoj.gov

2,755^th place

1,753^rd place

1archive-it.org

910^th place

593^rd place

1findlaw.com

1,478^th place

868^th place

1justice.gov

918^th place

556^th place

1va.gov

4,581^st place

2,821^st place

1forbes.com

54^th place

48^th place

1gmc-uk.org

low place

1cnie.org

low place

archive-it.org

wayback.archive-it.org

"Biopharmaceutical Company, Cephalon, to Pay $425 Million & Enter Plea to Resolve Allegations of Off-Label Marketing" (Press release). United States Department of Justice. September 29, 2008. Archived from the original on 2015-07-13.

axios.com

Brill, Steven (24 January 2017). "It's open season for off-label drug promotion". Axios. Retrieved 24 March 2017.

cancer.gov

"Why is off-label use of drugs so common in cancer treatment?". National Cancer Institute. Retrieved 2009-07-12.

cnie.org

"CRS Report for Congress: Agriculture: A Glossary of Terms, Programs, and Laws, 2005 Edition - Order Code 97-905". Archived 2013-09-23 at the Wayback Machine.

consumerreports.org

Carr, Teresa (9 November 2016). "FDA Considers Allowing Drug Ads for Unapproved Treatments". Consumer Reports. Retrieved 3 April 2017.

cornell.edu

law.cornell.edu

Buckman Co. v. Plaintiffs' Legal Comm., 531 U.S. 341 (U.S.S.Ct. 2001) ("the FDCA expressly states in part that '[n]othing in this chapter shall be construed to limit or interfere with the authority of a health care practitioner to prescribe or administer any legally marketed device to a patient for any condition or disease within a legitimate health care practitioner-patient relationship.' 21 U.S.C. § 396 (1994 ed., Supp. IV).").

doi.org

Randall S. Stafford (2008). "Regulating Off-Label Drug Use — Rethinking the Role of the FDA". N Engl J Med. 358 (14): 1427–1429. doi:10.1056/NEJMp0802107. PMID 18385495.
Briem, S; et al. (2011), "[Current "off label use" of methotrexate for chronic inflammatory rheumatic diseases]", Z Rheumatol, 70 (2): 123–128, doi:10.1007/s00393-010-0685-2, PMID 21267732.
David C. Radley; Stan N. Finkelstein; Randall S. Stafford (2006). "Off-label Prescribing Among Office-Based Physicians". Archives of Internal Medicine. 166 (9): 1021–1026. doi:10.1001/archinte.166.9.1021. PMID 16682577.
Alexander GC; Gallagher SA; Mascola A (2011). "Increasing off-label use of antipsychotic medications". Pharmacoepidemiology and Drug Safety. 20 (2): 177–184. doi:10.1002/pds.2082. PMC 3069498. PMID 21254289.
Bazzano; Mangione-Smith, Rita; Schonlau, Matthias; Suttorp, Marika; Brook, Robert H. (2009). "Off-label prescribing to children in the United States outpatient setting". Ambulatory Pediatrics. 9 (2): 81–8. doi:10.1016/j.acap.2008.11.010. PMID 19329098.
Christensen ML (2012). "Best pharmaceuticals for children act and pediatric research equity act: time for permanent status". Journal of Pediatric Pharmacology and Therapeutics. 17 (2): 140–41. doi:10.5863/1551-6776-17.2.140. PMC 3470432. PMID 23185144.
Frattarelli DA, Galinkin JL, Green TP, Johnson TD, Neville KA, Paul IM, Van Den Anker JN (2014). "Off-label use of drugs in children". Pediatrics. 133 (3): 563–567. doi:10.1542/peds.2013-4060. PMID 24567009.
Wing DA, Powers B, Hickok D (April 2010). "U.S. Food and Drug Administration Drug Approval: Slow Advances in Obstetric Care in the United States". Obstetrics & Gynecology. 115 (4): 825–33. doi:10.1097/AOG.0b013e3181d53843. PMID 20308845.
Frost, Jeana; Okun, Sally; Vaughan, Timothy; Heywood, James; Wicks, Paul (2011). "Patient-reported Outcomes as a Source of Evidence in Off-Label Prescribing: Analysis of Data From PatientsLikeMe". Journal of Medical Internet Research. 13 (1): e6. doi:10.2196/jmir.1643. PMC 3221356. PMID 21252034.
Sindrup SH, et al. (June 2005). "Antidepressants in the treatment of neuropathic pain". Basic & Clinical Pharmacology & Toxicology. 96 (6): 399–409. doi:10.1111/j.1742-7843.2005.pto_96696601.x. PMID 15910402.

druganddevicelawblog.com

Beck, James M.; Azari, Elizabeth D. (1998). "FDA, Off-Label Use, and Informed Consent: Debunking Myths and Misconceptions" (PDF). Food and Drug Law Journal. 53 (1): 76–80. PMID 11795338. Retrieved 21 September 2022.

fda.gov

"Development & Approval Process (Drugs)". Food and Drug Administration. 2009-10-27. Archived from the original on June 3, 2009. Retrieved 2011-11-21.
"The Office of Prescription Drug Promotion (OPDP)". Food and Drug Administration. 2008-03-25. Archived from the original on June 16, 2009. Retrieved 2011-11-21.

findlaw.com

blogs.findlaw.com

"Off-Label Use Promotion is Protected Free Speech". Findlaw. 2012-12-04. Retrieved 2014-06-26.

forbes.com

Herper, Matthew (17 October 2013). "Why The FDA Is Right To Block Amarin's Push To Market Fish Oil To Millions". Forbes.

gmc-uk.org

General Medical Council (December 2014) [first published February 2013]. "Good Practice in Prescribing and Managing Medicines and Devices" (PDF) (published guidance). General Medical Council. pp. 10–11. Retrieved 24 May 2018.

justice.gov

"Warner-Lambert to Pay $430 Million to Resolve Criminal & Civil Health Care Liability Relating to Off-Label Promotion" (Press release). United States Department of Justice. 2004-05-13. Retrieved 2013-04-30.

medicinenet.com

"Nonstimulant Therapy (Strattera) and Other ADHD Drugs". MedicineNet. Archived from the original on 2016-03-05. Retrieved 2015-02-03.

medscape.com

"New Agents and Second-line Therapies for Attention-Deficit/Hyperactivity Disorder". Medscape.

nih.gov

pubmed.ncbi.nlm.nih.gov

Randall S. Stafford (2008). "Regulating Off-Label Drug Use — Rethinking the Role of the FDA". N Engl J Med. 358 (14): 1427–1429. doi:10.1056/NEJMp0802107. PMID 18385495.
Briem, S; et al. (2011), "[Current "off label use" of methotrexate for chronic inflammatory rheumatic diseases]", Z Rheumatol, 70 (2): 123–128, doi:10.1007/s00393-010-0685-2, PMID 21267732.
David C. Radley; Stan N. Finkelstein; Randall S. Stafford (2006). "Off-label Prescribing Among Office-Based Physicians". Archives of Internal Medicine. 166 (9): 1021–1026. doi:10.1001/archinte.166.9.1021. PMID 16682577.
Alexander GC; Gallagher SA; Mascola A (2011). "Increasing off-label use of antipsychotic medications". Pharmacoepidemiology and Drug Safety. 20 (2): 177–184. doi:10.1002/pds.2082. PMC 3069498. PMID 21254289.
Bazzano; Mangione-Smith, Rita; Schonlau, Matthias; Suttorp, Marika; Brook, Robert H. (2009). "Off-label prescribing to children in the United States outpatient setting". Ambulatory Pediatrics. 9 (2): 81–8. doi:10.1016/j.acap.2008.11.010. PMID 19329098.
Christensen ML (2012). "Best pharmaceuticals for children act and pediatric research equity act: time for permanent status". Journal of Pediatric Pharmacology and Therapeutics. 17 (2): 140–41. doi:10.5863/1551-6776-17.2.140. PMC 3470432. PMID 23185144.
Frattarelli DA, Galinkin JL, Green TP, Johnson TD, Neville KA, Paul IM, Van Den Anker JN (2014). "Off-label use of drugs in children". Pediatrics. 133 (3): 563–567. doi:10.1542/peds.2013-4060. PMID 24567009.
Wing DA, Powers B, Hickok D (April 2010). "U.S. Food and Drug Administration Drug Approval: Slow Advances in Obstetric Care in the United States". Obstetrics & Gynecology. 115 (4): 825–33. doi:10.1097/AOG.0b013e3181d53843. PMID 20308845.
Frost, Jeana; Okun, Sally; Vaughan, Timothy; Heywood, James; Wicks, Paul (2011). "Patient-reported Outcomes as a Source of Evidence in Off-Label Prescribing: Analysis of Data From PatientsLikeMe". Journal of Medical Internet Research. 13 (1): e6. doi:10.2196/jmir.1643. PMC 3221356. PMID 21252034.
Sindrup SH, et al. (June 2005). "Antidepressants in the treatment of neuropathic pain". Basic & Clinical Pharmacology & Toxicology. 96 (6): 399–409. doi:10.1111/j.1742-7843.2005.pto_96696601.x. PMID 15910402.
Beck, James M.; Azari, Elizabeth D. (1998). "FDA, Off-Label Use, and Informed Consent: Debunking Myths and Misconceptions" (PDF). Food and Drug Law Journal. 53 (1): 76–80. PMID 11795338. Retrieved 21 September 2022.

ncbi.nlm.nih.gov

Alexander GC; Gallagher SA; Mascola A (2011). "Increasing off-label use of antipsychotic medications". Pharmacoepidemiology and Drug Safety. 20 (2): 177–184. doi:10.1002/pds.2082. PMC 3069498. PMID 21254289.
Christensen ML (2012). "Best pharmaceuticals for children act and pediatric research equity act: time for permanent status". Journal of Pediatric Pharmacology and Therapeutics. 17 (2): 140–41. doi:10.5863/1551-6776-17.2.140. PMC 3470432. PMID 23185144.
Frost, Jeana; Okun, Sally; Vaughan, Timothy; Heywood, James; Wicks, Paul (2011). "Patient-reported Outcomes as a Source of Evidence in Off-Label Prescribing: Analysis of Data From PatientsLikeMe". Journal of Medical Internet Research. 13 (1): e6. doi:10.2196/jmir.1643. PMC 3221356. PMID 21252034.

npr.org

"Prozac Isn't The Same In A Kid's Body". Day to Day. NPR. 2008-10-22. Retrieved 2011-11-21.

nytimes.com

Thomas, Katie (7 May 2015). "Drugmaker Sues F.D.A. Over Right to Discuss Off-Label Uses". The New York Times. Retrieved 17 May 2017.
Pollack, Andrew (7 August 2015). "Court Forbids F.D.A. From Blocking Truthful Promotion of Drug". The New York Times.
Thomas, Katie (8 March 2016). "F.D.A. Deal Allows Amarin to Promote Drug for Off-Label Use". The New York Times.

usdoj.gov

"Biopharmaceutical Company, Cephalon, to Pay $425 Million & Enter Plea to Resolve Allegations of Off-Label Marketing" (Press release). United States Department of Justice. September 29, 2008. Archived from the original on 2015-07-13.

va.gov

pbm.va.gov

VHA Pharmacy Benefits Management Strategic Healthcare Group and the Medical Advisory Panel (October 2005). "National PBM Drug Monograph Omega-3-acid ethyl esters (Lovaza, formerly Omacor)".

washingtonpost.com

McGinley, Laurie; Johnson, Carolyn Y. (10 March 2017). "Trump to select Scott Gottlieb, a physician with deep drug-industry ties, to run the FDA". Washington Post. Retrieved 24 March 2017.

web.archive.org

"Nonstimulant Therapy (Strattera) and Other ADHD Drugs". MedicineNet. Archived from the original on 2016-03-05. Retrieved 2015-02-03.
"Development & Approval Process (Drugs)". Food and Drug Administration. 2009-10-27. Archived from the original on June 3, 2009. Retrieved 2011-11-21.
"The Office of Prescription Drug Promotion (OPDP)". Food and Drug Administration. 2008-03-25. Archived from the original on June 16, 2009. Retrieved 2011-11-21.
"CRS Report for Congress: Agriculture: A Glossary of Terms, Programs, and Laws, 2005 Edition - Order Code 97-905". Archived 2013-09-23 at the Wayback Machine.

webmd.com

"Treatment Options for ADHD / ADD in Children and Teens". WebMD.